ISSN 0022-3565; 1521-0103;
22 papers in the library · 40 citations · publishing 1981-2023
J Pharmacol Exp Ther January 20, 2023 Laura B. Kozell, Amy J. Eshleman, Tracy L. Swanson et al. 40 citations
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter.
J Pharmacol Exp Ther May 13, 2010
Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.
J Pharmacol Exp Ther September 1, 1996
LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
J Pharmacol Exp Ther July 1, 1996
Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat.
J Pharmacol Exp Ther February 1, 1996
A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA.
J Pharmacol Exp Ther February 1, 1996
Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies.
J Pharmacol Exp Ther February 1, 1996
Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations.
J Pharmacol Exp Ther June 1, 1995
Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
J Pharmacol Exp Ther May 1, 1995
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits.
J Pharmacol Exp Ther October 1, 1994
Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine.
J Pharmacol Exp Ther June 1, 1994
Effects of LSD on Ca++ currents in central 5-HT-containing neurons: 5-HT1A receptors may play a role in hallucinogenesis.
J Pharmacol Exp Ther August 1, 1993
3,4-Methylenedioxymethamphetamine, serotonin and memory.
J Pharmacol Exp Ther 1993
Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells.
J Pharmacol Exp Ther October 1, 1992
Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist.
J Pharmacol Exp Ther May 1, 1992
Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.
J Pharmacol Exp Ther 1992
Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats.
J Pharmacol Exp Ther November 1, 1991
Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors.
J Pharmacol Exp Ther September 1, 1991
(+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist.
J Pharmacol Exp Ther September 1, 1988
Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
J Pharmacol Exp Ther December 1, 1987
Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats.
J Pharmacol Exp Ther 1984
Differential effects of hallucinogenic drugs on the activity of serotonin-containing neurons in the nucleus centralis superior and nucleus raphe pallidus in freely moving cats.
J Pharmacol Exp Ther October 1, 1981
Differential antagonism by metergoline of the behavioral effects of indolealkylamine and phenethylamine hallucinogens in the rat.